Climb Bio, Inc. financial data

Symbol
CLYM on Nasdaq
Industry
Pharmaceutical Preparations
Location
20 William Street, Suite 145, Wellesley Hills, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Eliem Therapeutics, Inc. (to 9/20/2024)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.97K % +80.9%
Debt-to-equity 1.98 % -49.2%
Return On Equity -42.2 % -25.8%
Return On Assets -41.4 % -28.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.2M shares +144%
Common Stock, Shares, Outstanding 67.2M shares +145%
Entity Public Float 13.2M USD -5.04%
Common Stock, Value, Issued 7K USD +133%
Weighted Average Number of Shares Outstanding, Basic 67M shares +148%
Weighted Average Number of Shares Outstanding, Diluted 67M shares +148%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.4M USD -34%
General and Administrative Expense 13.1M USD -52.5%
Operating Income (Loss) -76.2M USD -70.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -69.1M USD -76.2%
Earnings Per Share, Basic -2.12 USD/shares -27.7%
Earnings Per Share, Diluted -2.12 USD/shares -27.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 146M USD +155%
Marketable Securities, Current 47.2M USD -5.8%
Cash, Cash Equivalents, and Short-term Investments 124M USD -23.4%
Assets, Current 198M USD +75.8%
Operating Lease, Right-of-Use Asset 12K USD -95.8%
Other Assets, Noncurrent 0 USD -100%
Assets 222M USD +97.1%
Accounts Payable, Current 291K USD -60.5%
Accrued Liabilities, Current 3.05M USD +72.6%
Liabilities, Current 3.42M USD +18%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 3.42M USD +14.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 201K USD
Retained Earnings (Accumulated Deficit) -221M USD -45.4%
Stockholders' Equity Attributable to Parent 219M USD +99.4%
Liabilities and Equity 222M USD +97.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.82M USD +88%
Net Cash Provided by (Used in) Financing Activities 15K USD +1400%
Net Cash Provided by (Used in) Investing Activities 13.8M USD +137%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 67.2M shares +145%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 146M USD +155%
Deferred Tax Assets, Valuation Allowance 20.9M USD +24.4%
Deferred Tax Assets, Gross 20.9M USD +24%
Operating Lease, Liability 585K USD -15.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -68.9M USD -78.2%
Lessee, Operating Lease, Liability, to be Paid 611K USD -17.8%
Operating Lease, Liability, Current 58K USD -85.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15K USD -95.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 342K USD +45.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 172K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 17.1M USD +38.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15K USD 0%
Share-based Payment Arrangement, Expense 5.1M USD -62.2%